论文部分内容阅读
Though phase I clinical trial of immunotherapy for Alzheimer's disease(AD) with inoculated Aβ42 in humans had been proven to be effective,phase II immunotherapy trial was discontinued in 2002 because a few patients developed significant inflammatory r